APO Research
Talk to an analyst

APO RESEARCH · REPORT

CD40 Ligand

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global CD40 Ligand Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025185 pages

Choose your research edition.

Industry ResearchCD40 Ligand Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal CD40 Ligand Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal CD40 Ligand Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD40 Ligand Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal CD40 Ligand Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global CD40 Ligand market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for CD40 Ligand is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CD40 Ligand is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CD40 Ligand is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for CD40 Ligand is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of CD40 Ligand include Biogen, Inc., XL-protein GmbH, Targovax AS, MedImmune, LLC, Juno Therapeutics Inc., ImmuNext, Inc., eTheRNA Immunotherapies NV and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global CD40 Ligand market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CD40 Ligand and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CD40 Ligand sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the CD40 Ligand market size, projected growth trends, production technologies, key applications, and end-use industries.

CD40 Ligand Segment by Company

Biogen, Inc.

XL-protein GmbH

Targovax AS

MedImmune, LLC

Juno Therapeutics Inc.

ImmuNext, Inc.

eTheRNA Immunotherapies NV

Bristol-Myers Squibb Company

CD40 Ligand Segment by Type

ISF-35

MegaCD40L

MEDI-4920

LOAd-700

Others

CD40 Ligand Segment by Application

Hepatitis B

Ovarian Cancer

Liver Cancer

Bladder Cancer

Others

CD40 Ligand Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD40 Ligand market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD40 Ligand and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD40 Ligand.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the CD40 Ligand market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of CD40 Ligand manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of CD40 Ligand in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of CD40 Ligand in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. CD40 Ligand Industry Trends Table 2. CD40 Ligand Industry Drivers Table 3. CD40 Ligand Industry Opportunities and Challenges Table 4. CD40 Ligand Industry Restraints Table 5. Global CD40 Ligand Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global CD40 Ligand Revenue Market Share by Manufacturers (2021-2026) Table 7. Global CD40 Ligand Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global CD40 Ligand Sales Market Share by Manufacturers Table 9. Global CD40 Ligand Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global CD40 Ligand Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global CD40 Ligand Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global CD40 Ligand Manufacturers, Product Type & Application Table 13. Global CD40 Ligand Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global CD40 Ligand by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of ISF-35 Table 17. Major Manufacturers of MegaCD40L Table 18. Major Manufacturers of MEDI-4920 Table 19. Major Manufacturers of LOAd-700 Table 20. Major Manufacturers of Others Table 21. Global CD40 Ligand Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global CD40 Ligand Sales by Type (2021-2026) & (K Units) Table 23. Global CD40 Ligand Sales by Type (2027-2032) & (K Units) Table 24. Global CD40 Ligand Sales Market Share by Type (2021-2026) Table 25. Global CD40 Ligand Sales Market Share by Type (2027-2032) Table 26. Global CD40 Ligand Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global CD40 Ligand Revenue by Type (2021-2026) & (K Units) Table 28. Global CD40 Ligand Revenue by Type (2027-2032) & (K Units) Table 29. Global CD40 Ligand Revenue Market Share by Type (2021-2026) Table 30. Global CD40 Ligand Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hepatitis B Table 32. Major Manufacturers of Ovarian Cancer Table 33. Major Manufacturers of Liver Cancer Table 34. Major Manufacturers of Bladder Cancer Table 35. Major Manufacturers of Others Table 36. Global CD40 Ligand Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global CD40 Ligand Sales by Application (2021-2026) & (K Units) Table 38. Global CD40 Ligand Sales by Application (2027-2032) & (K Units) Table 39. Global CD40 Ligand Sales Market Share by Application (2021-2026) Table 40. Global CD40 Ligand Sales Market Share by Application (2027-2032) Table 41. Global CD40 Ligand Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global CD40 Ligand Revenue by Application (2021-2026) & (K Units) Table 43. Global CD40 Ligand Revenue by Application (2027-2032) & (K Units) Table 44. Global CD40 Ligand Revenue Market Share by Application (2021-2026) Table 45. Global CD40 Ligand Revenue Market Share by Application (2027-2032) Table 46. Global CD40 Ligand Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global CD40 Ligand Sales by Region (2021-2026) & (K Units) Table 48. Global CD40 Ligand Sales Market Share by Region (2021-2026) Table 49. Global CD40 Ligand Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global CD40 Ligand Sales Forecasted Market Share by Region (2027-2032) Table 51. North America CD40 Ligand Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America CD40 Ligand Sales by Country (2021-2026) & (K Units) Table 53. North America CD40 Ligand Sales by Country (2027-2032) & (K Units) Table 54. Europe CD40 Ligand Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe CD40 Ligand Sales by Country (2021-2026) & (K Units) Table 56. Europe CD40 Ligand Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific CD40 Ligand Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific CD40 Ligand Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific CD40 Ligand Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa CD40 Ligand Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa CD40 Ligand Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa CD40 Ligand Sales by Country (2027-2032) & (K Units) Table 63. Global CD40 Ligand Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global CD40 Ligand Revenue by Region (2021-2026) & (US$ Million) Table 65. Global CD40 Ligand Revenue by Region (2027-2032) & (US$ Million) Table 66. Global CD40 Ligand Revenue Market Share by Region (2021-2026) Table 67. Global CD40 Ligand Revenue Market Share by Region (2027-2032) Table 68. Biogen, Inc. Company Information Table 69. Biogen, Inc. Business Overview Table 70. Biogen, Inc. CD40 Ligand Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Biogen, Inc. CD40 Ligand Product Portfolio Table 72. Biogen, Inc. Recent Development Table 73. XL-protein GmbH Company Information Table 74. XL-protein GmbH Business Overview Table 75. XL-protein GmbH CD40 Ligand Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. XL-protein GmbH CD40 Ligand Product Portfolio Table 77. XL-protein GmbH Recent Development Table 78. Targovax AS Company Information Table 79. Targovax AS Business Overview Table 80. Targovax AS CD40 Ligand Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Targovax AS CD40 Ligand Product Portfolio Table 82. Targovax AS Recent Development Table 83. MedImmune, LLC Company Information Table 84. MedImmune, LLC Business Overview Table 85. MedImmune, LLC CD40 Ligand Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. MedImmune, LLC CD40 Ligand Product Portfolio Table 87. MedImmune, LLC Recent Development Table 88. Juno Therapeutics Inc. Company Information Table 89. Juno Therapeutics Inc. Business Overview Table 90. Juno Therapeutics Inc. CD40 Ligand Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Juno Therapeutics Inc. CD40 Ligand Product Portfolio Table 92. Juno Therapeutics Inc. Recent Development Table 93. ImmuNext, Inc. Company Information Table 94. ImmuNext, Inc. Business Overview Table 95. ImmuNext, Inc. CD40 Ligand Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. ImmuNext, Inc. CD40 Ligand Product Portfolio Table 97. ImmuNext, Inc. Recent Development Table 98. eTheRNA Immunotherapies NV Company Information Table 99. eTheRNA Immunotherapies NV Business Overview Table 100. eTheRNA Immunotherapies NV CD40 Ligand Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. eTheRNA Immunotherapies NV CD40 Ligand Product Portfolio Table 102. eTheRNA Immunotherapies NV Recent Development Table 103. Bristol-Myers Squibb Company Company Information Table 104. Bristol-Myers Squibb Company Business Overview Table 105. Bristol-Myers Squibb Company CD40 Ligand Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Bristol-Myers Squibb Company CD40 Ligand Product Portfolio Table 107. Bristol-Myers Squibb Company Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. CD40 Ligand Distributors List Table 111. CD40 Ligand Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. CD40 Ligand Product Image Figure 2. Global CD40 Ligand Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD40 Ligand Market Size (2021-2032) & (US$ Million) Figure 4. Global CD40 Ligand Sales (2021-2032) & (K Units) Figure 5. Global CD40 Ligand Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 CD40 Ligand Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. ISF-35 Image Figure 9. MegaCD40L Image Figure 10. MEDI-4920 Image Figure 11. LOAd-700 Image Figure 12. Others Image Figure 13. Global CD40 Ligand Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global CD40 Ligand Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global CD40 Ligand Sales Market Share by Type (2021-2032) Figure 16. Global CD40 Ligand Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global CD40 Ligand Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global CD40 Ligand Revenue Market Share by Type (2021-2032) Figure 19. Hepatitis B Image Figure 20. Ovarian Cancer Image Figure 21. Liver Cancer Image Figure 22. Bladder Cancer Image Figure 23. Others Image Figure 24. Global CD40 Ligand Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global CD40 Ligand Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global CD40 Ligand Sales Market Share by Application (2021-2032) Figure 27. Global CD40 Ligand Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global CD40 Ligand Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global CD40 Ligand Revenue Market Share by Application (2021-2032) Figure 30. North America CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America CD40 Ligand Sales Market Share by Country (2021-2032) Figure 32. U.S. CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe CD40 Ligand Sales Market Share by Country (2021-2032) Figure 37. Germany CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific CD40 Ligand Sales Market Share by Country (2021-2032) Figure 44. China CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa CD40 Ligand Sales Market Share by Country (2021-2032) Figure 52. Brazil CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile CD40 Ligand Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global CD40 Ligand Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global CD40 Ligand Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America CD40 Ligand Revenue (2021-2032) & (US$ Million) Figure 63. North America CD40 Ligand Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe CD40 Ligand Revenue (2021-2032) & (US$ Million) Figure 65. Europe CD40 Ligand Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific CD40 Ligand Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific CD40 Ligand Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa CD40 Ligand Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa CD40 Ligand Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. CD40 Ligand Value Chain Figure 71. Manufacturing Cost Structure Figure 72. CD40 Ligand Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • ISF-35
  • MegaCD40L
  • MEDI-4920
  • LOAd-700
  • Others
Applications
  • Hepatitis B
  • Ovarian Cancer
  • Liver Cancer
  • Bladder Cancer
  • Others
Companies covered
  • Biogen, Inc.
  • XL-protein GmbH
  • Targovax AS
  • MedImmune, LLC
  • Juno Therapeutics Inc.
  • ImmuNext, Inc.
  • eTheRNA Immunotherapies NV
  • Bristol-Myers Squibb Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CD40 Ligand Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CD40 Ligand Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global CD40 Ligand Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global CD40 Ligand Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global CD40 Ligand Market Dynamics
  1. 2.1 CD40 Ligand Industry Trends
  2. 2.2 CD40 Ligand Industry Drivers
  3. 2.3 CD40 Ligand Industry Opportunities and Challenges
  4. 2.4 CD40 Ligand Industry Restraints
3 CD40 Ligand Market by Manufacturers
  1. 3.1 Global CD40 Ligand Revenue by Manufacturers (2021-2026)
  2. 3.2 Global CD40 Ligand Sales by Manufacturers (2021-2026)
  3. 3.3 Global CD40 Ligand Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global CD40 Ligand Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global CD40 Ligand Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global CD40 Ligand Manufacturers, Product Type & Application
  7. 3.7 Global CD40 Ligand Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global CD40 Ligand Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 CD40 Ligand Players Market Share by Revenue in 2025
  11. 3.8.3 2025 CD40 Ligand Tier 1, Tier 2, and Tier 3
4 CD40 Ligand Market by Type
  1. 4.1 CD40 Ligand Type Introduction
  2. 4.1.1 ISF-35
  3. 4.1.2 MegaCD40L
  4. 4.1.3 MEDI-4920
  5. 4.1.4 LOAd-700
  6. 4.1.5 Others
  7. 4.2 Global CD40 Ligand Sales by Type
  8. 4.2.1 Global CD40 Ligand Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global CD40 Ligand Sales by Type (2021-2032)
  10. 4.2.3 Global CD40 Ligand Sales Market Share by Type (2021-2032)
  11. 4.3 Global CD40 Ligand Revenue by Type
  12. 4.3.1 Global CD40 Ligand Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global CD40 Ligand Revenue by Type (2021-2032)
  14. 4.3.3 Global CD40 Ligand Revenue Market Share by Type (2021-2032)
5 CD40 Ligand Market by Application
  1. 5.1 CD40 Ligand Application Introduction
  2. 5.1.1 Hepatitis B
  3. 5.1.2 Ovarian Cancer
  4. 5.1.3 Liver Cancer
  5. 5.1.4 Bladder Cancer
  6. 5.1.5 Others
  7. 5.2 Global CD40 Ligand Sales by Application
  8. 5.2.1 Global CD40 Ligand Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global CD40 Ligand Sales by Application (2021-2032)
  10. 5.2.3 Global CD40 Ligand Sales Market Share by Application (2021-2032)
  11. 5.3 Global CD40 Ligand Revenue by Application
  12. 5.3.1 Global CD40 Ligand Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global CD40 Ligand Revenue by Application (2021-2032)
  14. 5.3.3 Global CD40 Ligand Revenue Market Share by Application (2021-2032)
6 Global CD40 Ligand Sales by Region
  1. 6.1 Global CD40 Ligand Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CD40 Ligand Sales by Region (2021-2032)
  3. 6.2.1 Global CD40 Ligand Sales by Region (2021-2026)
  4. 6.2.2 Global CD40 Ligand Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CD40 Ligand Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America CD40 Ligand Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe CD40 Ligand Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe CD40 Ligand Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific CD40 Ligand Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific CD40 Ligand Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa CD40 Ligand Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa CD40 Ligand Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global CD40 Ligand Revenue by Region
  1. 7.1 Global CD40 Ligand Revenue by Region
  2. 7.1.1 Global CD40 Ligand Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global CD40 Ligand Revenue by Region (2021-2026)
  4. 7.1.3 Global CD40 Ligand Revenue by Region (2027-2032)
  5. 7.1.4 Global CD40 Ligand Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America CD40 Ligand Revenue (2021-2032)
  8. 7.2.2 North America CD40 Ligand Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe CD40 Ligand Revenue (2021-2032)
  11. 7.3.2 Europe CD40 Ligand Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific CD40 Ligand Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific CD40 Ligand Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa CD40 Ligand Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa CD40 Ligand Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen, Inc.
  2. 8.1.1 Biogen, Inc. Company Information
  3. 8.1.2 Biogen, Inc. Business Overview
  4. 8.1.3 Biogen, Inc. CD40 Ligand Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biogen, Inc. CD40 Ligand Product Portfolio
  6. 8.1.5 Biogen, Inc. Recent Developments
  7. 8.2 XL-protein GmbH
  8. 8.2.1 XL-protein GmbH Company Information
  9. 8.2.2 XL-protein GmbH Business Overview
  10. 8.2.3 XL-protein GmbH CD40 Ligand Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 XL-protein GmbH CD40 Ligand Product Portfolio
  12. 8.2.5 XL-protein GmbH Recent Developments
  13. 8.3 Targovax AS
  14. 8.3.1 Targovax AS Company Information
  15. 8.3.2 Targovax AS Business Overview
  16. 8.3.3 Targovax AS CD40 Ligand Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Targovax AS CD40 Ligand Product Portfolio
  18. 8.3.5 Targovax AS Recent Developments
  19. 8.4 MedImmune, LLC
  20. 8.4.1 MedImmune, LLC Company Information
  21. 8.4.2 MedImmune, LLC Business Overview
  22. 8.4.3 MedImmune, LLC CD40 Ligand Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 MedImmune, LLC CD40 Ligand Product Portfolio
  24. 8.4.5 MedImmune, LLC Recent Developments
  25. 8.5 Juno Therapeutics Inc.
  26. 8.5.1 Juno Therapeutics Inc. Company Information
  27. 8.5.2 Juno Therapeutics Inc. Business Overview
  28. 8.5.3 Juno Therapeutics Inc. CD40 Ligand Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Juno Therapeutics Inc. CD40 Ligand Product Portfolio
  30. 8.5.5 Juno Therapeutics Inc. Recent Developments
  31. 8.6 ImmuNext, Inc.
  32. 8.6.1 ImmuNext, Inc. Company Information
  33. 8.6.2 ImmuNext, Inc. Business Overview
  34. 8.6.3 ImmuNext, Inc. CD40 Ligand Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ImmuNext, Inc. CD40 Ligand Product Portfolio
  36. 8.6.5 ImmuNext, Inc. Recent Developments
  37. 8.7 eTheRNA Immunotherapies NV
  38. 8.7.1 eTheRNA Immunotherapies NV Company Information
  39. 8.7.2 eTheRNA Immunotherapies NV Business Overview
  40. 8.7.3 eTheRNA Immunotherapies NV CD40 Ligand Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 eTheRNA Immunotherapies NV CD40 Ligand Product Portfolio
  42. 8.7.5 eTheRNA Immunotherapies NV Recent Developments
  43. 8.8 Bristol-Myers Squibb Company
  44. 8.8.1 Bristol-Myers Squibb Company Company Information
  45. 8.8.2 Bristol-Myers Squibb Company Business Overview
  46. 8.8.3 Bristol-Myers Squibb Company CD40 Ligand Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bristol-Myers Squibb Company CD40 Ligand Product Portfolio
  48. 8.8.5 Bristol-Myers Squibb Company Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 CD40 Ligand Value Chain Analysis
  2. 9.1.1 CD40 Ligand Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 CD40 Ligand Production Mode & Process
  6. 9.2 CD40 Ligand Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 CD40 Ligand Distributors
  9. 9.2.3 CD40 Ligand Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst